Plain language summary: EASE research on Oleogel-S10 birch bark extract in epidermolysis bullosa care

This Plain Language Summary of Publication article (PLSP) from Future Rare Diseases examined the EASE study, the largest clinical trial in epidermolysis bullosa (EB), a rare inherited condition causing fragile skin that blisters easily. Researchers tested Oleogel-S10, a birch bark extract gel, against a control treatment for 90 days, then gave all patients the gel for up to two years to evaluate its wound healing effectiveness and long-term safety.

Visit the site using this link to read the article.

This PLSP is based on two articles called

‘Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study’ and was published in the British Journal of Dermatology.

‘Long-term safety and efficacy of Oleogel-S10 (birch bark extract) in epidermolysis bullosa: 24-month results from the phase III EASE study’ and was published in the British Journal of Dermatology.

Visit Oxford Academic using the link to read the original article.

Visit Oxford Academic using the link to read the original article.

• birch bark extract
• birch triterpenes
• Epidermolysis Bullosa
• junctional and dystrophic EB
• long-term efficacy and safety
• Oleogel-S10
• plain language summary
• wound healing